Research literacy · Issue 01 · 11 October 2026
Peptide research: what a study can actually tell you
The useful question is not whether a peptide has a compelling headline. It is whether the evidence answers the question you care about.
Start with the original study
A social post is a starting point, not the evidence. Open the original paper. Look for the study design, the people enrolled, the comparison group and the length of follow-up.
Two widely discussed randomized trials in the New England Journal of Medicine studied adults with overweight or obesity who did not have diabetes. One followed participants for 68 weeks; the other for 72 weeks. Those details define the studies. They do not describe every patient or every product being discussed online.
Read beyond the headline
- Who was studied? Check inclusion and exclusion criteria. A finding in one group is not a promise for another.
- What was the comparison? A trial with a control group answers a different question from an uncontrolled report.
- What was measured? Distinguish the main outcome from exploratory findings. Read the limitations and safety reporting.
- What exact preparation was tested? Do not treat evidence for one studied medicine as evidence for every compounded or research-use product.
Keep research and access separate
FDA says unapproved versions of GLP-1 drugs do not undergo its review for safety, effectiveness and quality before marketing. A study link is not proof that an offered product is approved or appropriate for a particular person.
FDA: concerns with unapproved GLP-1 drugsThe brief, by email
Keep up without the noise.
Research context and pharmacy-policy updates, in plain language. No dosing guidance or product offers.
Educational editorial content. Crestpath provides business price comparisons, not healthcare products or medical advice.